

Description of Medical Areas
About the FDA Approved Listings
|
 |
Approved Drugs for Gastroenterology
Drugs Approved in 2008
Cimzia (Certolizumab Pegol); For the treatment of Crohn’s disease; UCB Inc.; Approved April 2008
Entereg (alvimopan); For the treatment of postoperative ileus; GlaxoSmithKline; Approved May 2008
Rotarix (Rotavirus Vaccine, Live, Oral); For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in pediatrics; GlaxoSmithKline; Approved April 2008
Sancuso (granisetron); For the treatment of chemotherapy-induced nausea and vomiting; ProStrakan; Approved September 2008
Tysabri (natalizumab); For the maintenance treatment of moderate to severe Crohn’s disease; Biogen IDEC; Approved January 2008
Drugs Approved in 2007
No approvals recorded for Gastroenterology in 2007.
Drugs Approved in 2006
Amitiza (lubiprostone); For the treatment of chronic idiopathic constipation; Sucampo/Takeda; Approved January 2006
Drugs Approved in 2005
No approvals recorded for Gastroenterology in 2005.
Drugs Approved in 2004
Avastin (bevacizumab); For the treatment of metastatic carcinoma of the colon or rectum; Genentech; Approved February 2004
Erbitux (cetuximab); For the treatment of EGFR-expressing, metastatic colorectal cancer; Imclone, Bristol-Myers Squibb; Approved February 2004
Drugs Approved in 2003
Aloxi (palonosetron); For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; MGI Pharma, Helsinn Healthcare; Approved August 2003
Emend (aprepitant); For the treatment of nausea and vomiting associated with chemotherapy; Merck; Approved March 2003
Drugs Approved in 2002
Aciphex (rabeprazole sodium); For the treatment of symptomatic gastroesophageal reflux disease; Eisai; Approved February 2002
Alinia (nitazoxanide); For the treatment Diarrhea caused by Cryptosporidium and Giardia in children.; Romark Laboratories; December 2002
Eloxatin (oxaliplatin/5-fluorouracil/leucovorin); For the treatment of colon or rectum carcinomas; Sanofi-Synthelabo; Approved August 2002
Gleevec (imatinib mesylate); For the treatment of gastrointestinal stromal tumors (GISTs); Novartis; Approved February 2002
Hepsera (adefovir dipivoxil); For the treatment of chronic hepatitis B in adults with evidence of active viral replication; Gilead Sciences; Approved September 2002
Orfadin (nitisinone); Capsules for the treatment of hereditary tyrosinemia type I; Orphan Pharmaceuticals; Approved January 2002
Pegasys (peginterferon alfa-2a); For the treatment of chronic hepatitis C who have compensated liver disease; Roche; Approved October 2002
Protonix (pantoprazole sodium) Delayed Release Tablets; Oral tablets for the treatment of gastroesophageal and pathological hypersecretory conditions; Wyeth Pharmaceuticals; Approved April 2002
SecreFlo (secretin); To aid in the diagnosis of pancreatic dysfunction and gastrinoma; Repligen; Approved April 2002
Zelnorm (tegaserod maleate) Tablets; For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation; Novartis; Approved July 2002
Zelnorm (tegaserod maleate) Tablets; For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation; Novartis; Approved July 2002
Drugs Approved in 2001
Canasa (mesalamine); For the treatment of active ulcerative proctitis; Axcan Scandipharm; Approved January 2001
Entocort EC (budesonide); Capsules for the treatment of mild-to-moderate, active Crohn's disease; AstraZeneca; Approved October 2001
Nexium (esomeprazole magnesium); For the eradication of Helicobacter pylori, the healing of erosive esophagitis, and the treatment of symptomatic GERD; AstraZeneca; Approved February 2001
Protonix (pantoprazole sodium) Intravenous Formulation; For the short-term treatment of gastroesophageal reflux disease; Wyeth-Ayerst Laboratories; Approved March 2001
Rebetol (ribavirin); For the treatment of chronic hepatitis C; Schering-Plough; Approved July 2001
Twinrix; For the prevention of hepatitis A and B; GlaxoSmithKline; Approved May 2001
Drugs Approved in 2000
Colazal (balsalazide disodium); Mild to moderately active ulcerative colitis; SALIX PHARMACEUTICALS; Approved July 2000
Lotronex (alosetron HCL) Tablets; Indicated for Irritable Bowel Syndrome (IBS) in females with diarrhea-predominant IBS; GlaxoWellcome; Approved February 2000
Pepcid Complete; For use in the relief of heartburn associated with acid indigestion and sour stomach; Merck; Approved October 2000
Protonix (pantoprazole sodium) Delayed-Release Tablets; For treatment of erosive esophagitis; Wyeth-Ayerst Laboratories; Approved February 2000
Visicol Tablet; For cleansing of the bowel as a preparation for colonoscopy, in adults 18 years of age and older; Inkine Pharmaceutical; Approved September 2000
Drugs Approved in 1999
Prevpac; Treatment for eradication of H. pylori; TAP Pharmaceuticals; Approved February 1999
Drugs Approved in 1998
Cimetidine; Generic equivalent of Tagamet HB 200; Pharmaceutical Formulations; Approved June 1998
PREVACID(R) (lansopraxole); Treatment of heartburn associated with GERD; TAP Pharmaceuticals; Approved April 1998
Prilosec; Treatment for heartburn; Astra Merck; Approved January 1998
Drugs Approved in 1997
Asacol (mesalamine); Treatment of ulcerative colitis; Procter & Gamble; Approved August 1997
Cimetadine Hydrochloride Oral Solution 300mg/5ml; Generic equivalent of Tagamet Oral Solution; Morton Grove Pharmaceuticals; Approved October 1997
Cimetidine Hydrochloride Oral Solution; Generic equivalent of Tagamet Oral Solution, 300 mg/5 ml; Hi-Tech Pharmacal; Approved October 1997
Prevpac; Treatment for duodenal ulcers; TAP Pharmaceuticals; Approved December 1997
Prochloroperazine; Generic equivalent of Compazine; Duramed Pharmaceuticals; Approved May 1997
Ranitidine Capsules; Generic equivalent of Zantac GELdose; Geneva Pharmaceuticals; Approved October 1997
Ranitidine Tablets; Generic equivalent of Zantac; Apotex; Approved September 1997
Urso; Treatment for primary biliary cirrhosis; Axcan Schwarz; Approved December 1997
Drugs Approved in 1996
Axid AR (nizatidine; Over-the-counter anti-ulcer treatment; Whitehall-Robins Healthcare; Approved May 1996
|
 |

Back to Centerwatch Drug Approvals

|